Your browser doesn't support javascript.
loading
Physical and cognitive impact following SARS-CoV-2 infection in a large population-based case-control study.
Holm, Hilma; Ivarsdottir, Erna V; Olafsdottir, Thorhildur; Thorolfsdottir, Rosa; Eythorsson, Elias; Norland, Kristjan; Gisladottir, Rosa; Jonsdottir, Gudrun; Unnsteinsdottir, Unnur; Sveinsdottir, Kristin E; Jonsson, Benedikt A; Andresdottir, Margret; Arnar, David O; Arnthorsson, Asgeir O; Birgisdottir, Kolbrún; Bjarnadottir, Kristbjorg; Bjarnadottir, Solveig; Bjornsdottir, Gyda; Einarsson, Gudmundur; Eiriksdottir, Berglind; Gardarsdottir, Elisabet Eir; Gislason, Thorarinn; Gottfredsson, Magnus; Gudmundsdottir, Steinunn; Gudmundsson, Julius; Gunnarsdottir, Kristbjorg; Helgadottir, Anna; Helgason, Dadi; Hinriksdottir, Ingibjorg; Ingvarsson, Ragnar F; Jonasdottir, Sigga S; Jonsdottir, Ingileif; Karlsdottir, Tekla H; Kristinsdottir, Anna M; Kristinsson, Sigurdur Yngvi; Kristjansdottir, Steinunn; Love, Thorvardur J; Ludviksdottir, Dora; Masson, Gisli; Norddahl, Gudmundur; Olafsdottir, Thorunn; Olafsson, Isleifur; Rafnar, Thorunn; Runolfsdottir, Hrafnhildur L; Saemundsdottir, Jona; Sigurbjornsson, Svanur; Sigurdardottir, Kristin; Sigurdsson, Engilbert; Sigurdsson, Martin I; Sigurdsson, Emil L.
Afiliação
  • Holm H; deCODE genetics/Amgen Inc., Reykjavik, Iceland. hilma.holm@decode.is.
  • Ivarsdottir EV; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Olafsdottir T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Thorolfsdottir R; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Eythorsson E; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Norland K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Gisladottir R; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsdottir G; School of Humanities, University of Iceland, Reykjavik, Iceland.
  • Unnsteinsdottir U; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Sveinsdottir KE; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsson BA; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Andresdottir M; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Arnar DO; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Arnthorsson AO; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Birgisdottir K; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Bjarnadottir K; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Bjarnadottir S; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Bjornsdottir G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Einarsson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Eiriksdottir B; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Gardarsdottir EE; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Gislason T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Gottfredsson M; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Gudmundsdottir S; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Gudmundsson J; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Gunnarsdottir K; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Helgadottir A; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Helgason D; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Hinriksdottir I; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Ingvarsson RF; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonasdottir SS; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Jonsdottir I; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Karlsdottir TH; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Kristinsdottir AM; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Kristinsson SY; National Institute of Hearing and Speech in Iceland, Reykjavik, Iceland.
  • Kristjansdottir S; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Love TJ; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Ludviksdottir D; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Masson G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Norddahl G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Olafsdottir T; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Olafsson I; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Rafnar T; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Runolfsdottir HL; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Saemundsdottir J; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Sigurbjornsson S; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
  • Sigurdardottir K; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
  • Sigurdsson E; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurdsson MI; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
  • Sigurdsson EL; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Commun Med (Lond) ; 3(1): 94, 2023 Jul 06.
Article em En | MEDLINE | ID: mdl-37414856
ABSTRACT

BACKGROUND:

Persistent symptoms are common after SARS-CoV-2 infection but correlation with objective measures is unclear.

METHODS:

We invited all 3098 adults who tested SARS-CoV-2 positive in Iceland before October 2020 to the deCODE Health Study. We compared multiple symptoms and physical measures between 1706 Icelanders with confirmed prior infection (cases) who participated, and 619 contemporary and 13,779 historical controls. Cases participated in the study 5-18 months after infection.

RESULTS:

Here we report that 41 of 88 symptoms are associated with prior infection, most significantly disturbed smell and taste, memory disturbance, and dyspnea. Measured objectively, cases had poorer smell and taste results, less grip strength, and poorer memory recall. Differences in grip strength and memory recall were small. No other objective measure associated with prior infection including heart rate, blood pressure, postural orthostatic tachycardia, oxygen saturation, exercise tolerance, hearing, and traditional inflammatory, cardiac, liver, and kidney blood biomarkers. There was no evidence of more anxiety or depression among cases. We estimate the prevalence of long Covid to be 7% at a median of 8 months after infection.

CONCLUSIONS:

We confirm that diverse symptoms are common months after SARS-CoV-2 infection but find few differences between cases and controls in objective parameters measured. These discrepancies between symptoms and physical measures suggest a more complicated contribution to symptoms related to prior infection than is captured with conventional tests. Traditional clinical assessment is not expected to be particularly informative in relating symptoms to a past SARS-CoV-2 infection.
Persistent symptoms are commonly reported after SARS-CoV-2 infection, and this is often described as long Covid. We compared different symptoms reported following SARS-CoV- 2 infection with the results obtained during various medical evaluations that are often used to assess health, such as blood tests, smell tests, taste tests, hearing tests, etc. We compared symptoms and test results between 1,706 Icelanders who had been infected previously with SARS-CoV-2 infection (cases) and 14,398 individuals who had not been infected (controls). Out of 88 assessed symptoms, 41 were more common in cases than controls. However, relatively few differences were seen in the results obtained from the various medical evaluations (cases had poorer smell and taste test results, slightly less grip strength, and slightly poorer memory recall than controls). The differences seen between symptoms and results of medical evaluations suggests that conventional clinical tests may not be informative in relating symptoms to a past SARS-CoV-2 infection.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Islândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Commun Med (Lond) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Islândia